Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
long intergenic non-protein coding RNA 1963 (LINC01963)
- Target
- LINC01963
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic lncRNA, Other
01
Overview
"Long intergenic non-protein coding RNA 1963" (LINC01963) is a human long non-coding RNA gene found in the intergenic regions of the genome, meaning it does not overlap with protein-coding sequences. It is classified as lncRNA and is involved in gene expression regulation, with a particular role in cancer biology. LINC01963 acts as a tumor suppressor in pancreatic carcinoma by inhibiting cell proliferation and invasion, inducing apoptosis, and modulating post-transcriptional regulation networks, including negative regulation of miR-641 and positive regulation of TMEFF2. Co-expression with TSC2 suggests a possible role in autophagy regulation and mTOR pathway inhibition, further linking LINC01963 to cellular stress and cancer pathways. Overall, LINC01963 does not encode a protein but exerts biological influence at the RNA level, making it a key member of non-coding RNA regulatory networks in cancer.
- Other names
- DKFZp434H1419PKI55LINC01963
02
Mechanism of action
Not applicable; no approved pharmacological agents directly target LINC01963. Modulation in research uses genetic tools to upregulate or knock down expression.
03
Biological functions
Negative regulation of cell proliferationInduction of apoptosisInhibition of tumor invasion and migrationNegative regulation of miR-641 and positive influence on TMEFF2 activity in pancreatic carcinomaPotential involvement in autophagy regulation via positive co-expression with tuberous sclerosis 2 (TSC2), associated with mTOR pathway inhibition
04
Disease associations
Cancer: Downregulation associated with pancreatic cancer progression; functions as a tumor suppressor in pancreatic carcinomaCancer: May be relevant in oral and oropharyngeal squamous cell carcinoma through autophagy-related mechanismsOther: General cancer relevance as a member of the lncRNA family with roles in tumorigenesis
05
Safety considerations
None reported specific to therapeutic targeting, as LINC01963 is not a direct therapeutic targetChallenges for lncRNA-based therapies generally include tissue-specific expression, delivery, and off-target effects
06
Biomarkers
Expression level of LINC01963 may serve as a prognostic biomarker in pancreatic carcinoma; lower levels are associated with more aggressive disease and worse prognosisPotentially useful in autophagy-related lncRNA signatures in oral/oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on long intergenic non-protein coding RNA 1963 (LINC01963).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on long intergenic non-protein coding RNA 1963 (LINC01963).